ATE375795T1 - Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs - Google Patents

Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Info

Publication number
ATE375795T1
ATE375795T1 AT06011784T AT06011784T ATE375795T1 AT E375795 T1 ATE375795 T1 AT E375795T1 AT 06011784 T AT06011784 T AT 06011784T AT 06011784 T AT06011784 T AT 06011784T AT E375795 T1 ATE375795 T1 AT E375795T1
Authority
AT
Austria
Prior art keywords
dexamethasone
cancer
treatment
combination therapy
therapy
Prior art date
Application number
AT06011784T
Other languages
German (de)
English (en)
Inventor
Esteban Cvitkovic
George Daniel Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Jean-Louis Misset
Chris Twelves
Hoff Daniel D Von
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE375795T1 publication Critical patent/ATE375795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT06011784T 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs ATE375795T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
ATE375795T1 true ATE375795T1 (de) 2007-11-15

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06011784T ATE375795T1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1716853B9 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN1360503A (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE375795T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE60045720D1 (enExample)
DK (3) DK1702618T3 (enExample)
ES (2) ES2272279T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1702618T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
HK1244713A1 (zh) * 2016-02-04 2018-08-17 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
BR112022020812A2 (pt) 2020-04-15 2022-11-29 Ever Valinject Gmbh Composição farmacêutica compreendendo trabectedina e um aminoacido, formulação liofilizada e uma solução de injeção intravenosa compreendendo dita composição
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
JP2562162B2 (ja) * 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
AU746713B2 (en) * 1996-11-05 2002-05-02 Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU758100B2 (en) * 1998-04-06 2003-03-13 Board Of Trustees Of The University Of Illinois, The Semi-synthetic ecteinascidins
JP4583598B2 (ja) * 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
DK1280809T3 (da) 2000-04-12 2005-11-07 Pharma Mar Sa Antitumorecteinascidinderivater
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) * 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
CA2583464A1 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
PT1702618E (pt) 2008-01-11
LU91418I2 (fr) 2008-05-13
BR0010531A (pt) 2002-06-04
FR08C0013I2 (fr) 2009-10-30
HUP0201187A2 (en) 2002-09-28
SI1716853T1 (sl) 2011-10-28
IL146434A (en) 2008-03-20
SI1176964T1 (sl) 2007-02-28
EP1716853A2 (en) 2006-11-02
DE60030554T8 (de) 2008-01-10
PT1176964E (pt) 2007-01-31
IL146434A0 (en) 2002-07-25
JP5777562B2 (ja) 2015-09-09
NO2008005I1 (no) 2008-06-09
EP1716853B9 (en) 2011-09-28
NO2008005I2 (enExample) 2010-09-27
CA2373794C (en) 2005-10-11
NO20015516D0 (no) 2001-11-12
CY1105818T1 (el) 2011-02-02
PT1716853E (pt) 2011-05-12
CN1360503A (zh) 2002-07-24
US20070275942A1 (en) 2007-11-29
DK1176964T3 (da) 2007-01-15
CY1112753T1 (el) 2016-02-10
CN1679631A (zh) 2005-10-12
AU777417B2 (en) 2004-10-14
TR200103819T2 (tr) 2002-04-22
MXPA01011562A (es) 2002-07-30
CA2373794A1 (en) 2000-11-23
EP1702618A3 (en) 2006-12-27
EP1702618A2 (en) 2006-09-20
LU91418I9 (enExample) 2019-01-02
WO2000069441A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
AU2005200180B9 (en) 2008-05-29
CY2008007I2 (el) 2009-11-04
EP1702618B1 (en) 2007-10-17
DE60036826D1 (de) 2007-11-29
HUS1500001I1 (hu) 2016-08-29
PL352931A1 (en) 2003-09-22
SK287580B6 (sk) 2011-03-04
MY164077A (en) 2017-11-30
JP2012149095A (ja) 2012-08-09
DE60030554T2 (de) 2007-09-13
HU229866B1 (en) 2014-10-28
ES2272279T3 (es) 2007-05-01
DK1702618T3 (da) 2008-02-25
AU2005200180B2 (en) 2007-12-13
SI1702618T1 (sl) 2008-02-29
EP1716853B1 (en) 2011-03-09
EP1716853A3 (en) 2006-11-15
ES2294756T3 (es) 2008-04-01
DE60036826T2 (de) 2008-08-28
NL300337I1 (nl) 2008-05-01
EP1176964B8 (en) 2007-10-10
DE60045720D1 (de) 2011-04-21
KR20020019914A (ko) 2002-03-13
NL300337I2 (nl) 2008-09-01
FR08C0013I1 (enExample) 2008-05-30
NZ515423A (en) 2004-04-30
DE122008000013I1 (de) 2008-08-07
CZ20014081A3 (cs) 2002-11-13
PL198185B1 (pl) 2008-06-30
CZ301482B6 (cs) 2010-03-17
EP1176964A1 (en) 2002-02-06
CN100477993C (zh) 2009-04-15
CY2008007I1 (el) 2009-11-04
JP2002544231A (ja) 2002-12-24
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
DK1716853T3 (da) 2011-06-27
NO20015516L (no) 2002-01-11
ATE338552T1 (de) 2006-09-15
NO324564B1 (no) 2007-11-19
ATE500830T1 (de) 2011-03-15
UA74782C2 (uk) 2006-02-15
CY1107143T1 (el) 2010-07-28
HUP0201187A3 (en) 2002-11-28
US8119638B2 (en) 2012-02-21
BG65680B1 (bg) 2009-06-30
AR028476A1 (es) 2003-05-14
EP1176964B1 (en) 2006-09-06
SK16442001A3 (sk) 2002-03-05
AU4597500A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
DE60036826D1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
EP1080113A4 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60032226D1 (de) Verfahren zur induktion von krebszellentod und tumorregression
ATE400283T1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
DE60112423D1 (de) Verwendung von substituierten distamycin-acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
DE69935156D1 (de) hCG THERAPIE ZUR BEHANDLUNG VON METASTATISCHEM BRUSTKREBS
ATE420074T1 (de) Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen